Millions in Africa and the rest of the developing world suffer from HIV/AIDS, malaria, and tuberculosis. What is the best way to treat them? Since President George W. Bush's pledge of $15 billion to fight these diseases, controversy has developed over strategies and methods. Last month at a conference in Botswana, delegates wrestled with the issue of fixed-dose combinations of anti-retroviral drugs, which have not been approved by the Food and Drug Administration but were "pre-qualified" by the World Health Organization. Are such drugs safe? Or does their use risk the development of new resistant strains of HIV? Activists have accused drug companies, with the support of the Bush administration, of trying to block the use of cheaper generics, but new research indicates that only a small fraction of drugs in the developing world is patented. This conference will focus on ways that policymakers should confront the obstacles to treating pandemic diseases in the developing world.
What's new on AEI
|The Census Bureau and Obamacare: Dumb decision? Yes. Conspiracy? No.
|A 'three-state solution' for Middle East peace|
|Give the CBO long-range tools|
|The coming collapse of India's communists|
Join a diverse group of panelists — including sociologists, education experts, and students — for a discussion of how public policy and culture can help families lay a firmer foundation for their children’s educational success, and of how the effects of paternal involvement vary by socioeconomic background.
This event will coincide with the release of a new report by AEI’s Mary Habeck, which analyzes why current national security policy is failing to stop the advancement of al Qaeda and its affiliates and what the US can do to develop a successful strategy to defeat this enemy.
During this event, experts with many different views on the ACA will offer their predictions for the future.